Rationale Taken From Trial Data for Using Daratumumab in Multiple MyelomaJanuary 19th 2021
During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.
Sequencing of CD19-Directed Therapy Is Still Up for DebateJanuary 17th 2021
Gilles Salles, MD, PhD, discussed sequencing of CD-19 directed therapies for a 74-year-old patient with diffuse large B-cel lymphoma during a Targeted Oncology Case-Based Peer Perspective Roundtable event.
Details of Different Therapies and Modalities Decide Treatment of CLL in the Second LineJanuary 13th 2021
For the second-line treatment of patients with chronic lymphocytic leukemia, the armamentarium includes many therapies and strategies. Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute, discussed how to select treatment for patients during a Targeted Oncology Case-Based Peer Perspectives event.
Expert Discusses Genomic Testing and Trials Pertinent to Treating Prostate CancerJanuary 12th 2021
During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.
Systemic Therapy Remains a Successful Strategy for Patients Refusing Surgery for CSCCJanuary 11th 2021
For patients with cutaneous squamous cell carcinoma who refuse surgery as a treatment for their disease, systemic therapies like cemiplimab, nivolumab, avelumab, and pembrolizumab can still improve outcomes, explained Asim Amin, MD, PhD, a medical oncologist, Levine Cancer Institute. Atrium Health during a Targeted Oncology Case-Based Peer Perspectives event.
Early-Phase Trial Data of EGFR Inhibitors Lead to Successful Use of Osimertinib in Resected EGFR+ NSCLCJanuary 10th 2021
Osimertinib has been a successful therapy for the treatment of EGFR-positive non–small cell lung cancer, surpassing the effects of chemotherapy. In he adjuvant setting, physicians questions when and how to use osimertinib.
Trials Conducted in Unresectable Locally Advanced Lung Adenocarcinoma Show Path for TreatmentJanuary 9th 2021
Multiple treatment options exist for patients with unresectable locally advanced lung adenocarcinoma. Zofia Piotrowska, MD, examined the options during a Targeted Oncology Case-Based Peer Perspectives event.
Expert Compares Vismodegib and Sonidegib for Treatment of Infiltrative BCCJanuary 7th 2021
Solly Chedid, MD, led a discussion with a group of peers about the treatment of infiltrative basal cell carcinoma in a 88-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other DrugsJanuary 4th 2021
During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.
Hormonal Therapies Useful in Different Situations for Prostate CancerDecember 15th 2020
During a Targeted Oncology Case Based Peer Perspectives event, Daniel J. George, MD, professor of Medicine, professor in Surgery Member, Duke Cancer Institute Department of Medicine Duke University School of Medicine, discuss various hormonal therapies for the treatment of prostate cancer.